You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 2, February 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Argon Green vs Krypton Red Laser Photocoagulation of Extrafoveal Choroidal Neovascular Lesions

One-Year Results in Age-Related Macular Degeneration

The Canadian Ophthalmology Study Group

Arch Ophthalmol. 1993;111(2):181-185.


Abstract

• This multicenter randomized controlled clinical trial performed in Canada was designed to determine whether krypton red laser or argon green laser is superior for treatment of choroidal neovascularization located between 200 and 2500µm from the center of the foveal avascular zone in patients with agerelated macular degeneration. Two hundred ten patients were randomly assigned to treatment with either argon green or krypton red laser, of whom 191 (91%) were determined eligible. Of the eligible patients, 185 (97%) had sufficient follow-up for a comparison of primary-outcome visual acuity at 1 year. We conclude, with 95% confidence, that the krypton red laser is no better than the argon green laser for the treatment of well-defined extrafoveal choroidal neovascularization.



Author Affiliations

A complete listing of the participants in the Canadian Ophthalmology Study Group (COSG) appears on page 185. The COSG has no proprietary interest in either the argon green laser or the krypton red laser.


Footnotes

Accepted for publication July 31, 1992.

Prepared for the COSG by Alan F. Cruess, MD; Andrew Willan, PhD; and Margaret Ballantyne, MS, Queen's University, Kingston, Ontario.

Reprint requests to COSG, Room 3011, Etherington Hall, Queen's University, Kingston, Ontario, Canada K7L 3N6 (Dr Cruess).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Argon Green vs Krypton Red Laser Photocoagulation for Extrafoveal Choroidal Neovascularization: One-Year Results in Ocular Histoplasmosis
The Canadian Ophthalmology Study Group
Arch Ophthalmol 1994;112:1166-1173.
ABSTRACT  

Evaluation of Argon Green vs Krypton Red Laser for Photocoagulation of Subfoveal Choroidal Neovascularization in the Macular Photocoagulation Study
Macular Photocoagulation Study (MPS) Group
Arch Ophthalmol 1994;112:1176-1184.
ABSTRACT  

Does Wavelength Matter When Photocoagulating Eyes With Macular Degeneration or Diabetic Retinopathy?
Bressler
Arch Ophthalmol 1993;111:177-180.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.